Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF SEPTEMBER 11, 2011 FBO #3578
MODIFICATION

65 -- Affymetrix Exon Array and microRNA gene chips and reagents

Notice Date
9/9/2011
 
Notice Type
Modification/Amendment
 
NAICS
325414 — Biological Product (except Diagnostic) Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
 
ZIP Code
20852
 
Solicitation Number
NCI-110180-LG
 
Archive Date
9/28/2011
 
Point of Contact
Laura Glockner, Phone: 3014968607
 
E-Mail Address
laura.glockner@nih.gov
(laura.glockner@nih.gov)
 
Small Business Set-Aside
N/A
 
Description
This presolicitation notice has been modified to change to commercial procedures. Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Popular Genetics plans to procure on a sole source basis from Affymetrix Inc., 3420 Central Expressway, Santa Clara, CA 95051 for Affymetrix Exon Array and microRNA gene chips and reagents. This acquisition will be processed under the procedures for FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 325414 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The overall mission of the Laboratory of Population Genetics (LPG) is to gain a better understanding of the genetic etiology of cancer and its related phenotypes. The LPG undertakes this mission through a systems approach, integrating genetics with multiple high-throughput molecular characterizations enabled through informatics. The LPG's systems strategy utilizes experimental design and analytic approaches that result in reduced complexity. Reduced complexity amplifies signal relative to noise, making it feasible to extract insights from the complex adaptive system that underpins cancer etiology. The genetic basis of cancer is unquestionably complex. It is a disease of altered genes, manifested at the cellular level. It generates and requires systemic changes in the individual. Factors affecting individuals define susceptibility at the population level. To effectively treat and prevent the disease, insight must be gained and integrated from each of these dimensions. The LPG synergistically employs common strategies to achieve its mission. Using Affymetrix gene chip methodologies, the Buetow Laboratory has determined that aberrant gene regulation may be important in the etiology of hepatocellular carcinoma (HCC). The Laboratory of Population Genetics, of the Center for Cancer Research, of the NCI requires the use of the Affymetrix exon and microRNA chips to continue its ongoing studies to better understand gene dysregulation in the etiology of hepatocellular carcinoma. The purchase of these reagents will enable the LPG to further validate and extend its findings on how gene dysregulation contributes to the etiology of hepatocellular carcinoma. Affymetrix is the only known source for these proprietary reagents which are required to continue the LPG's studies. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on September 13, 2011 11:00 a.m. EST. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Laura Glockner, Contract Specialist at laura.glockner@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110180-LG on all correspondence.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110180-LG/listing.html)
 
Record
SN02569959-W 20110911/110910000423-3dc149ee5287001497453feafa4efb5f (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.